Trevi Therapeutics Stock Price, News & Analysis

Trevi Therapeutics (NASDAQ: TRVI) has announced the pricing of an underwritten public offering of 17.4 million shares of common stock at $5.75 per share, aiming to raise $100 million before deducting underwriting costs. The company, which is developing Haduvio for chronic cough in IPF and RCC patients, has also granted underwriters a 30-day option to purchase up to 2.61 million additional shares. The offering is expected to close around June 5, 2025, with Morgan Stanley, Leerink Partners, Stifel, and Cantor serving as joint book-running managers. The shares are being offered through a shelf registration statement on Form S-3 that was declared effective by the SEC on August 15, 2023.

Trevi Therapeutics (NASDAQ: TRVI) has announced a proposed public offering of $100 million worth of common stock shares, with an additional 30-day option for underwriters to purchase up to $15 million more shares. The clinical-stage biopharmaceutical company, which is developing Haduvio (oral nalbuphine ER) for chronic cough treatment in IPF and RCC patients, will offer all shares through joint book-running managers Morgan Stanley, Leerink Partners, Stifel, and Cantor. The offering will be conducted under a previously filed shelf registration statement that was declared effective by the SEC on August 15, 2023. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

Trevi Therapeutics (NASDAQ: TRVI) announced positive Phase 2b CORAL trial results for Haduvio in treating chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The trial met its primary endpoint with significant reductions in 24-hour cough frequency across all dose groups, with the highest dose (108mg BID) achieving a -43.3% placebo-adjusted reduction. The drug demonstrated rapid efficacy at Week 2 and was well-tolerated, with similar discontinuation rates between treatment (5.6%) and placebo (5.0%) groups. Secondary endpoints showed significant improvements in cough severity and patient-reported outcomes. The company plans to meet with the FDA and initiate Phase 3 trials in first half of 2026.

Trevi Therapeutics (NASDAQ: TRVI) has scheduled a conference call and webcast for June 2nd, 2025, at 8:30 a.m. ET to present topline results from their Phase 2b CORAL trial. The trial evaluates Haduvio (oral nalbuphine ER) for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF). The presentation will be accessible via webcast with audio and slides, and participants can join by phone at (877) 870 4263 (domestic) or (412) 317 0790 (international). A 30-day replay will be available on the company's website after the event. Haduvio is also being investigated for refractory chronic cough (RCC) treatment.

Trevi Therapeutics (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing Haduvio™ (oral nalbuphine ER) for chronic cough treatments, announced its participation in three major conferences in June 2025. The company will present at the American Cough Conference (June 6-7) discussing RIVER trial demographics for refractory chronic cough. At the CPDD 87th Annual Scientific Meeting (June 14-18), they will present research on nalbuphine's human abuse potential. Finally, at the BIO International Convention (June 16-19), the company will deliver a corporate presentation. Key executives, including CEO Jennifer Good and other senior management, will represent Trevi at these events.

Trevi Therapeutics (NASDAQ: TRVI) has presented additional analyses from its Phase 2a RIVER trial of Haduvio™ (oral nalbuphine ER) for refractory chronic cough (RCC). The trial met its primary endpoint with a 67% reduction in 24-hour cough frequency from baseline and 57% on a placebo-adjusted basis (p<0.0001). Key findings include:

• Statistically significant responder analyses across all doses at 30%, 50%, and 75% thresholds
• Significant improvement in Leicester Cough Questionnaire at Day 21
• Adverse events were more common during initial exposure (27mg BID) but decreased over time
• Most discontinuations occurred in first two weeks due to CNS and GI-related adverse events

The company awaits Phase 2b trial results in IPF patients with chronic cough to determine future development strategy.

Trevi Therapeutics (NASDAQ: TRVI) reported Q1 2025 financial results and key developments for its drug candidate Haduvio. The company announced positive Phase 2a RIVER trial results showing a significant 67% reduction in 24-hour cough frequency from baseline in refractory chronic cough patients. The Phase 2b CORAL trial for IPF patients with chronic cough completed enrollment and last patient visit, with topline results expected in Q2 2025. Financially, Trevi ended Q1 with $103.3 million in cash, providing runway into Q4 2026. The company reported R&D expenses of $7.8 million (down from $8.8 million in Q1 2024) and G&A expenses of $3.7 million (up from $3.1 million), resulting in a net loss of $10.3 million compared to $10.9 million in the same period last year.

Trevi Therapeutics (NASDAQ: TRVI) has scheduled its Q1 2025 financial results and corporate update conference call for May 8, 2025, at 4:30 p.m. ET. The company, which is developing Haduvio™ (oral nalbuphine ER) for chronic cough treatment in patients with idiopathic pulmonary fibrosis (IPF) or refractory chronic cough (RCC), will host the event via conference call and live audio webcast. Investors can join by dialing (877) 870 4263 (domestic) or (412) 317 0790 (international). The webcast will be available through the 'Investors & News' section on Trevi's website and archived for 30 days afterward.

Trevi Therapeutics (Nasdaq: TRVI), developing Haduvio™ (oral nalbuphine ER) for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), has announced its participation in three major investor conferences this April 2025.

The company will present at the following events:

• 24th Annual Needham Virtual Healthcare Conference (April 7-10) with a corporate presentation on April 7 at 11:00-11:40 a.m. ET
• Jones Healthcare and Technology Innovation Conference (April 8-9) in Las Vegas, with a presentation on April 9 at 11:00-11:20 a.m. PT
• Piper Sandler Spring Biopharma Symposium (April 16-17) in Boston